This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toure-Balde, A.
Right arrow Articles by Druilhe, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toure-Balde, A.
Right arrow Articles by Druilhe, P.

 Previous Article  |  Next Article 

Infection and Immunity, March 2009, p. 1189-1196, Vol. 77, No. 3
0019-9567/09/$08.00+0     doi:10.1128/IAI.00780-07
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Evidence for Multiple B- and T-Cell Epitopes in Plasmodium falciparum Liver-Stage Antigen 3{triangledown}

Aissatou Toure-Balde,1 Blanca-Liliana Perlaza,2 Jean-Pierre Sauzet,2 Mouhamadou Ndiaye,1 Georgette Aribot,1 Adama Tall,1 Cheikh Sokhna,3 Christophe Rogier,4 Giampietro Corradin,5 Christian Roussilhon,2 and Pierre Druilhe2*

Institut Pasteur de Dakar, Dakar, Senegal,1 Bio-Medical Parasitology Unit, Institut Pasteur, Paris, France,2 Institut de Recherche et de Developpement, Dakar, Senegal,3 Institut de Medecine Tropicale du Service de Sante des Armees, Marseille, France,4 Institute of Biochemistry, University of Lausanne, Lausanne, Switzerland5

Received 8 June 2007/ Returned for modification 8 September 2007/ Accepted 1 January 2009

Liver-stage antigen 3 (LSA-3) is a new vaccine candidate that can induce protection against Plasmodium falciparum sporozoite challenge. Using a series of long synthetic peptides (LSP) encompassing most of the 210-kDa LSA-3 protein, a study of the antigenicity of this protein was carried out in 203 inhabitants from the villages of Dielmo (n = 143) and Ndiop (n = 60) in Senegal (the level of malaria transmission differs in these two villages). Lymphocyte responses to each individual LSA-3 peptide were recorded, some at high prevalences (up to 43%). Antibodies were also detected to each of the 20 peptides, many at high prevalence (up to 84% of responders), and were directed to both nonrepeat and repeat regions. Immune responses to LSA-3 were detectable even in individuals of less than 5 years of age and increased with age and hence exposure to malaria, although they were not directly related to the level of malaria transmission. Thus, several valuable T- and B-cell epitopes were characterized all along the LSA-3 protein, supporting the antigenicity of this P. falciparum vaccine candidate. Finally, antibodies specific for peptide LSP10 located in a nonrepeat region of LSA-3 were found significantly associated with a lower risk of malaria attack over 1 year of daily clinical follow-up in children between the ages of 7 and 15 years, but not in older individuals.

* Corresponding author. Mailing address: Bio-Medical Parasitology Unit, Institut Pasteur, 25 rue du Dr Roux, Paris 75015, France. Phone: 331 45 68 85 78. Fax: 331 45 68 86 40. E-mail: druilhe{at}pasteur.fr

{triangledown} Published ahead of print on 12 January 2009.

Editor: J. F. Urban, Jr.

Infection and Immunity, March 2009, p. 1189-1196, Vol. 77, No. 3
0019-9567/09/$08.00+0     doi:10.1128/IAI.00780-07
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»